Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related DiseasesMuscle Weakness, Neoplasms by Site, Neurologic Manifestations, Neuromuscular Manifestations, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, muscle tissue disorder, musculoskeletal system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndromeRecruitingPhase 12026-02-25NCT06626919

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Arcellx, Inc.5

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Columbia University Irving Medical CenterNew YorkUnited States234
Houston Methodist HospitalHoustonUnited States260
Karmanos Cancer InstituteDetroitUnited States153
Mayo ClinicRochesterUnited States664
Ohio State UniversityColumbusUnited States19
Oregon Health & Science University (OHSU)PortlandUnited States25
Stanford HospitalPalo AltoUnited States4
Temple University HospitalPhiladelphiaUnited States97
UCLA Medical CenterLos AngelesUnited States42
University of California, IrvineOrangeUnited States1
University of Minnesota Delaware Clinical Research UnitMinneapolisUnited States1
University of South Florida - Carol and Frank Morsani Center of Advanced HealthcareTampaUnited States1
UT Southwestern Medical CenterDallasUnited States210